Security key
04351P101
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 13,995,656
- Total 13F value
- $281,311,000
- Share change
- +119,062
- SEC-reported price per share
- $20.10
- Number of holders
- 22
- Value change
- +$4,791,129
- Number of buys
- 7
- Number of sells
- 13
- Shares outstanding
- 62,915,156
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2016
Institutions
22
Top holders
10
ASND full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2016
Previous quarter: Q2 2016
Ascendis Pharma A/S SEC filings
Ascendis Pharma A/S company facts
Broader feeds
Reporting periods
Holder history for CUSIP 04351P101
Recent filing periods:
Ownership snapshot
Top reported holders of ASND - Ascendis Pharma A/S - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
RA CAPITAL MANAGEMENT, L.P.
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
15/15
Latest evidence
30 Jun 2016
13F
Lead comparable stake: 5.4%
Showing 1-6 of 15 holder rows.
Quick read
RA CAPITAL MANAGEMENT, L.P. leads the comparable SEC ownership view at 5.4%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens RA CAPITAL MANAGEMENT, L.P.'s linked filing trail.
Comparable ownership
Top 5
RA CAPITAL MANAGEMENT, L.P.
5.4%
FMR LLC
4%
ORBIMED ADVISORS LLC
3.5%
Vivo Capital, LLC
2.8%
BAKER BROS. ADVISORS LP
1.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
5.4%
|
$45,289,000
3,412,857 shares
|
— | 30 Jun 2016 |
| FMR LLC |
13F
Company
|
4%
|
$33,345,000
2,512,824 shares
|
— | 30 Jun 2016 |
| ORBIMED ADVISORS LLC |
13F
Company
|
3.5%
|
$29,075,000
2,191,000 shares
|
— | 30 Jun 2016 |
| Vivo Capital, LLC |
13F
Company
|
2.8%
|
$23,446,000
1,766,832 shares
|
— | 30 Jun 2016 |
| BAKER BROS. ADVISORS LP |
13F
Company
|
1.2%
|
$9,893,000
745,521 shares
|
— | 30 Jun 2016 |
| VHCP Management II, LLC |
13F
Company
|
1.1%
|
$9,570,000
721,152 shares
|
— | 30 Jun 2016 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2016
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
22
Shares
13,995,656
Rows available
22
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2016 vs Q2 2016 Across Filers
Q2 2016 holders
23
Q3 2016 holders
22
Holder diff
-1
| Investor | Q2 2016 Shares | Q3 2016 Shares | Share Diff | Share Chg % | Q2 2016 value | Q3 2016 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend